ALNAQ — Allena Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Allena Pharmaceuticals Inc expected to post a loss of 21 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-BriaCell, Velodyne Lidar, Qualigen, Compass Minerals
U.S. STOCKS ON THE MOVE-Glaukos, American Airlines, Allied Healthcare, Apple
Brief: Allena Pharmaceuticals Announces $28 Million Registered Direct Offering
Brief: Allena Pharmaceuticals Provides Update on Clinical Development Programs
Allena Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Allena Pharmaceuticals Posts Q1 Loss Per Share $0.21
Brief: Allena Pharmaceuticals Inc - Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Brief: Allena Pharmaceuticals Files Prospectus Supplement Related To Issuance, Sale Of Up To $50 Million Of Common Stock
Brief: Allena Pharmaceuticals Reports Qtrly Loss Per Share $0.24
Brief: Allena Pharmaceuticals Says Appoints Richard D. Katz As Chief Financial Officer
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:32 PM
Brief: Orin Hirschman Reports 8.0% Passive Stake In Allena Pharmaceuticals Inc As Of January 20, 2021 - SEC Filing
Brief: Allena Pharmaceuticals Increases Previously Announced Bought Deal To $13.0 Million
Brief: Allena Pharmaceuticals Announces $10 Million Bought Deal Offering
Brief: Allena Pharma Announces Initial Data From Phase 1 Trial Of ALLN-346
Brief: Allena Pharmaceuticals Inc Files For Shelf Of Up To 6.1 Million Shares By Selling Stockholders - SEC Filing
Brief: Allena Pharmaceuticals Doses First Subject In Phase 1 Clinical Trial Of Alln-346, In Development For The Treatment Of Hyperuricemia In Patients With Gout And Advanced Chronic Kidney Disease
Brief: Allena Pharma Reports Q2 Loss Per Share Of $0.26